87629-12-7

Usage

Class

Pyrazolopyridines

Contains

Fluorophenyl group, methyl group, and tetrahydro group

Type of compound

Heterocyclic (contains a ring structure with at least two different elements as part of the ring)

Potential applications

Pharmaceutical industry (possesses biological activity, may be used in drug development or as a research tool)

Additional research needed

Yes

Upstream product

• 87628-25-9 5-acetyl-3-(4-fluorophenyl)-4,5,6,7-tetrahydro-1H-pyrazolo<4,3-c>pyridine 
• 87642-26-0 1-Acetyl-3-(4-fluoro-benzoyl)-piperidin-4-one 
• 55459-60-4 1-(4-(morpholin-4-yl)-3,6-dihydro-2H-pyridin-1-yl)ethanone 
• 32161-06-1 1-acetyl-4-piperidinone 
• 60-34-4 methylhydrazine 
• 87628-76-0 1-[3-(4-Fluoro-phenyl)-1-methyl-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone 

Relevant academic research and scientific papers

Dipeptidyl peptidase IV inhibitors derived from β-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazole

A series of β-aminoacylpiperidines bearing various fused five-membered heterocyclic rings was synthesized as dipeptidyl peptidase IV inhibitors. Potent and relatively selective inhibition could be obtained, depending on choice of heterocycle, regioisomerism, and substitution. In particular, one analog (74, DPP-IV IC50 = 26 nM) exhibited good oral bioavailability and acceptable half-life in the rat, albeit with rather high clearance.

Synthesis, in Vitro 3H>Prazosin Displacement, and in Vivo Activity of 3-Aryl-4,5,6,7-tetrahydropyrazolopyridines, a New Class of Antihypertensive Agents

A series of a new 3-aryl-4,5,6,7-tetrahydropyrazolopyridines was synthesized and screened for in vitro 3H>prazosin displacement activity.The results correlated well with their antihypertensive activity in spontaneous hypertensive rats.